University of California Los Angeles Medical Center, Los Angeles, California, USA.
Catheter Cardiovasc Interv. 2012 Apr 1;79(5):812-22. doi: 10.1002/ccd.23042. Epub 2011 Jul 25.
Data have emerged demonstrating the safety and efficacy of percutaneous coronary intervention (PCI) of the unprotected left main (ULM) artery. The 2009 American College of Cardiology/American Heart Association/Society for Cardiovascular Angiography and Interventions focused guidelines for PCI no longer state that ULM PCI is contraindicated in patients with anatomic conditions that are associated with a low risk of procedural complications and clinical conditions that predict an increased risk of adverse surgical outcomes. ULM PCI should be performed by operators with experience in the management of the anatomic complexities of left main and multivessel disease, specifically in issues relating to bifurcation disease, calcification, and hemodynamic support. Patients with ostial or shaft disease have lower risk of restenosis compared with distal bifurcation disease. Drug-eluting stents (DES) should be used whenever possible as they reduce clinical restenosis. Intravascular ultrasound is an integral component of the procedure as it provides accurate assessment of lesion severity and can confirm optimal stent expansion and apposition. Compliance with dual antiplatelet therapy for at least 12 months is essential if DES are used. A collaborative, multidisciplinary approach with a "Heart Team" represented by a cardiac surgeon, interventional cardiologist, and non-invasive cardiologist may optimize patient education and objective decision making when obtaining informed consent. Application of clinical and angiographic variables into risk models facilitates appropriate patient selection. Randomized clinical trials will address unanswered issues and help build consensus between cardiology and surgical societies to inform clinical decision making and optimize the outcomes for patients with ULM coronary artery disease.
已经有数据表明,经皮冠状动脉介入治疗(PCI)无保护左主干(ULM)动脉是安全有效的。2009 年美国心脏病学会/美国心脏协会/心血管血管造影和介入学会(ACC/AHA/SCAI)重点关注 PCI 的指南不再规定,对于解剖结构条件与手术并发症风险低相关,且临床情况预测手术不良结局风险增加的患者,ULM PCI 是禁忌证。应由具有管理左主干和多血管疾病解剖复杂性经验的操作人员进行 ULM PCI,特别是在与分叉病变、钙化和血流动力学支持相关的问题上。与远端分叉病变相比,开口或主干病变的患者再狭窄风险较低。只要可能,应使用药物洗脱支架(DES),因为它们可降低临床再狭窄的风险。血管内超声是该手术的一个组成部分,因为它可提供对病变严重程度的准确评估,并可确认支架的最佳扩张和贴壁。如果使用 DES,则必须遵守双联抗血小板治疗至少 12 个月。如果采用多学科协作的“心脏团队”方法,由心脏外科医生、介入心脏病专家和无创心脏病专家组成,可能会优化患者教育和获得知情同意时的客观决策。将临床和血管造影变量应用于风险模型有助于对患者进行适当的选择。随机临床试验将解决未解决的问题,并帮助心脏病学和外科学会之间建立共识,为 ULM 冠状动脉疾病患者提供临床决策依据,并优化其结果。